Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

• Published in: Diabetes care Vol. 47; no. 3; pp. 467 - 470
• Main Authors: Roubille, François, Bouabdallaoui, Nadia, Kouz, Simon, Waters, David D., Diaz, Rafael, Maggioni, Aldo P., Pinto, Fausto J., Grégoire, Jean C., Gamra, Habib, Kiwan, Ghassan S., Berry, Colin, López-Sendón, José, Koenig, Wolfgang, Delorme, Laurent, Elbaz, Meyer, Coste, Pierre, Provencher, Mylène, Bassevitch, Zohar, Blondeau, Lucie, L’Allier, Philippe L., Guertin, Marie-Claude, Tardif, Jean-Claude
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.03.2024
• Subjects: Anti-inflammatory agents; Cardiovascular disease; Cardiovascular System; Clinical trials; Colchicine; Colchicine - adverse effects; Colchicine - therapeutic use; Coronary Artery Disease - drug therapy; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Heart attacks; Heart diseases; Humans; Life Sciences; Myocardial infarction; Myocardial Infarction - drug therapy; Myocardial Infarction - prevention & control; Placebos
• ISSN: 0149-5992; 1935-5548; 1935-5548; 0149-5992
• DOI: 10.2337/dc23-1825

The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT). COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44-0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008). Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention.